It is uniquely baffling how poorly the market is pricing B2Y even after this. In all my years have never seen anything like this. Could either mean I am grossly wrong or an amazing opportunity.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025